ClinicalTrials.gg
CompletedNCT00697346Updated May 31, 2019Results posted

Study of MLN8237 in Participants With Advanced Hematological Malignancies

A Phase 1 interventional study of Alisertib in B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma and Diffuse Large B-cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-31.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States — 57 open to participants now, 95 under way, 6 of them phase 3. Lymphoma, B-Cell, Marginal Zone · United States.

Enrollment
163rd of 557
58 · median 36
Started
2008
with 33 others
Phase 1
247 of 674
22 open now
Registered
360th of 674
by date

Among the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, this one is the 163rd largest by enrollment of the 557 interventional ones that give a count, is one of 34 that started in 2008, is one of 247 in phase 1, and was the 360th registered.

Lymphoma, B-Cell, Marginal Zone

875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

57 of the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.

Read the detailed description

The drug being tested in this study is called alisertib. Alisertib is being tested to treat people who have advanced hematological malignancies. This study determined the dose-limiting toxicity, maximum tolerated dose, safety and pharmacokinetics (how the drug moves through the body) for alisertib when given once or twice a day for 7 to 21 days.

This open label study enrolled 58 patients. Participants were enrolled in one of 3 treatment groups:

  • Part 1: Powder-in-Capsule (PIC) Dose Escalation (alisertib 25 mg PIC, orally twice daily [BID] on Day 1 [loading dose] and then alisertib 25 or 35 mg PIC once daily [QD] for 21 days (D), or alisertib 35, 45, 65 or 90 mg PIC, orally, QD for 14D) in 28-day cycles
  • Part 1: Enteric-coated Tablet (ECT) Dose Escalation (alisertib 40 mg, ECT, orally, QD for 14D or alisertib 30, 40 or 50 mg, orally, BID for 7D) in 28-day cycles
  • Part 2: Participants with Peripheral T-cell Lymphoma (PTCL) (alisertib 50 mg ECT, orally, BID for 7D) in 21-day cycles

All participants received treatment for 12 months or until their disease progressed or they experienced unacceptable alisertib-related toxicity. This multi-center trial was conducted in the United States. The overall time to participate in this study was 422 days. Participants made multiple visits to the clinic, including a final visit 30 days after receiving their last dose of alisertib for a follow-up assessment.

03

Conditions studied

  • B-cell Follicular Lymphoma
  • B-cell Marginal Zone Lymphoma
  • Diffuse Large B-cell Lymphoma
  • B-cell Mantle Cell Lymphoma
  • B-cell Small Lymphocytic Lymphoma
  • B-Cell Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Waldenstrom's Macroglobulinemia
  • Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Enteropathy Associated T-cell Lymphoma
  • NK Lymphoma

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • disease and a or cytologically confirmed hematological of the following type for which standard curative treatment does not exist or is no longer effective:

    • B-cell Follicular lymphoma
    • B-cell Marginal zone lymphoma
    • Diffuse large B-cell lymphoma
    • B-cell Mantle cell lymphoma
    • B-cell Small lymphocytic lymphoma (SLL)
    • B-Cell Chronic lymphocytic leukemia (B-CLL)
    • Multiple myeloma
    • Waldenstrom's macroglobulinemia
    • Noncutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
    • Angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma, enteropathy associated T-cell lymphoma (EATCL), NK lymphoma (NKL)
  • Participants with diffuse large B-cell lymphoma must have failed, be ineligible for, or have refused an stem cell transplant. There is no restriction regarding the maximum number of prior regimens.
  • Aged 18 years or older
  • (ECOG) performance status 0 to 2
  • Radiographically or clinically evaluable disease for Part 1 of this study and for Part 2 of this study
  • Suitable venous access for the conduct of blood sampling for MLN8237 pharmacokinetics (PK)
  • Recovered from the reversible effects of prior antineoplastic treatment (with the exception of alopecia and Grade 1 neuropathy)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating
  • Treatment with enzyme inducers within 14 days prior to the first dose of MLN8237 as specified in the protocol
  • Prior allogeneic bone marrow (or other organ) transplantation
  • Newly diagnosed or uncontrolled cancer-related central nervous system (CNS) disease
  • Systemic antineoplastic treatment within 21 days preceding the first dose of study treatment. Exceptions requiring a 42-day recovery period from last treatment include: Nitrosoureas, mitomycin C or Rituximab, alemtuzumab (Campath®), or other unconjugated therapeutic antibody (21 days if clear evidence of progressive disease)
  • Treatment with radioimmunoconjugates or toxin immunoconjugates such as ibritumomab tiuxetan (Zevalin™), or tositumomab (Bexxar®) within 56 days preceding the first dose of study treatment
  • Antineoplastic treatment with within 21 days preceding the first dose of study treatment
  • Radiotherapy involving \<25% of the hematopoietically active bone marrow within 21 days preceding first dose of study treatment
  • Radiotherapy involving ≥25% of the hematopoietically active bone marrow within 42 days preceding first dose of study treatment
  • Inability to swallow capsules or known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of MLN8237. Examples include, but are not limited to, partial gastrectomy, history of small intestine surgery, and celiac disease.
  • History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe
  • Known or suspected (HIV) positive or surface antigen-positive status, or known or suspected active infection. Testing is not required in the absence of clinical findings or suspicion.
  • Participants who fail to meet laboratory values as specified in the protocol during the screening period
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Part 1: PIC Dose Escalation

    Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, (QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.

    Drug: Alisertib

  • Experimental
    Part 1: ECT Dose Escalation

    Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).

    Drug: Alisertib

  • Experimental
    Part 2: PTCL

    Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).

    Drug: Alisertib

Interventions

  • Alisertib (MLN8237) PIC or ECT

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicity (DLT)

    DLT was evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and was defined as any of the following events related to therapy with alisertib:1. Grade 4 neutropenia lasting ≥7 consecutive days, 2. Grade 4 neutropenia with fever and/or infection 3. Platelet count \<25,000/mm\^3 4. Grade 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis 5. Grade 3 or greater diarrhea despite maximal supportive therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\<1 week) Grade 3 fatigue 7. Treatment delay of \>21 days due to failure of adequate hematologic or non-hematologic recovery from previous cycle of treatment 8. Other alisertib related non-hematologic toxicities ≥Grade 2 that, in the opinion of the investigator required a dose reduction or discontinuation of therapy with alisertib.

    Time frame: From first dose of study drug to 30 days after the last dose (up to 422 days)

  2. Maximum Tolerated Dose (MTD) of Alisertib

    MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 participants.

    Time frame: From first dose of study drug to 30 days after the last dose (up to 422 days)

  3. Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose

  4. Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21

    Time frame: Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose

  5. Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose

  6. Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21

    Time frame: Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose

  7. AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21

    Time frame: Cycle 1 Day 21 predose and at multiple time points (up to 6 hours) postdose

  8. Terminal Half-Life (t1/2) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21

    Time frame: Cycle 1 Day 21 predose and at multiple time points (up to 6 hours) postdose

  9. Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21

    Time frame: Cycle 1 Day 21 predose and at multiple time points (up to 6 hours) postdose

  10. Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21

    Time frame: Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose

  11. CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21

    Time frame: Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose

  12. Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose

  13. Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  14. Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose

  15. Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  16. AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  17. Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  18. Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  19. CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  20. Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose

  21. Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  22. Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose

  23. Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  24. AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  25. Terminal Half Life for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  26. Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  27. CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14

    Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose

  28. Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 12 hours) postdose

  29. Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7

    Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose

  30. Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 12 hours) postdose

  31. Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7

    Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose

  32. AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1

    Time frame: Cycle 1 Days 1 predose and at multiple timepoints (up to 12 hours) postdose

  33. AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7

    Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose

  34. Terminal Half-Life (t1/2) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7

    Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose

  35. Accumulation Ratio (Rac) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7

    Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose

  36. Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7

    Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose

  37. CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7

    Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose

Secondary outcomes

  1. Best Overall Response Rate Based on Investigator's Assessment

    Best overall response rate is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the Investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and the definition for PR includes at least a 50% decrease in sum of the product of the diameters and no new lesions.

    Time frame: Baseline and every 2 cycles up to Month 12 until disease progression, 30 days after end of treatment (up to 422 days)

  2. Duration of Response (DOR)

    DOR is defined as the time from the date of first documentation of a response (either CR or PR) to the date of first documentation of progressive disease (PD) according to International Working Group (IWG) criteria. CR is defined as the disappearance of all evidence of disease and the definition for PR includes at least a 50% decrease in sum of the product of the diameters and no new lesions. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.

    Time frame: Baseline and every 2 cycles up to Month 12 until disease progression, 30 days after end of treatment (up to 422 days)

  3. Number of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1

    One peripheral blood sample (approximately 4 mL) was to be obtained on Day 1 of Cycle 1 prior to the first dose of alisertib to genotype participants for polymorphisms in UGT1A1 because UGT1A1 is one of the enzymes responsible for glucuronidation of alisertib, which is expected to contribute to the clearance of alisertib. wt=wild type. \*28=polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression. Not determined = blood sample was not evaluable.

    Time frame: Cycle 1 Day 1 predose

  4. Number of Participants With Polymorphisms in Aurora A Kinase

    Time frame: Cycle 1 Day 1 predose

07

Results

Posted May 31, 2019

Participant flow

Participants took part in the study at 10 investigative sites in the United States from 11 July 2008 to19 October 2016.

Participant flow — Overall Study
MilestonePart 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCL
Started28282
Completed021
Not completed28261
Withdrew: Adverse event450
Withdrew: Progressive disease19180
Withdrew: Symptomatic deterioration010
Withdrew: Withdrawal by subject220
Withdrew: Reason not specified301

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicity (DLT)

DLT was evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and was defined as any of the following events related to therapy with alisertib:1. Grade 4 neutropenia lasting ≥7 consecutive days, 2. Grade 4 neutropenia with fever and/or infection 3. Platelet count \<25,000/mm\^3 4. Grade 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis 5. Grade 3 or greater diarrhea despite maximal supportive therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\<1 week) Grade 3 fatigue 7. Treatment delay of \>21 days due to failure of adequate hematologic or non-hematologic recovery from previous cycle of treatment 8. Other alisertib related non-hematologic toxicities ≥Grade 2 that, in the opinion of the investigator required a dose reduction or discontinuation of therapy with alisertib.

Time frame:
From first dose of study drug to 30 days after the last dose (up to 422 days)
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicity (DLT)
participantsAlisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21DAlisertib 35 mg PIC QD 14DAlisertib 45 mg PIC QD 14DAlisertib 65 mg PIC QD 14DAlisertib 90 mg PIC QD 14DAlisertib 40 mg ECT QD 14DAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
Number of Participants With Dose-Limiting Toxicity (DLT)1201222001
PrimaryMaximum Tolerated Dose (MTD) of Alisertib

MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 participants.

Time frame:
From first dose of study drug to 30 days after the last dose (up to 422 days)
Reported as:
Number · mg BID for 7 days
Maximum Tolerated Dose (MTD) of Alisertib
mg BID for 7 daysAlisertib
Maximum Tolerated Dose (MTD) of Alisertib50
PrimaryCmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1
nMAlisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21D
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1833.2 ± 49.51078.3 ± 26.4
PrimaryCmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame:
Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
nMAlisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21D
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 211337.6 ± 57.81451.9 ± 26.2
PrimaryTmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Median · hours (h)
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1
hours (h)Alisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21D
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 12.0 (2.0 to 3.3)2.0 (1.1 to 5.2)
PrimaryTmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame:
Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
hAlisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21D
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 212.0 (1.0 to 5.0)2.0 (2.0 to 2.0)
PrimaryAUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame:
Cycle 1 Day 21 predose and at multiple time points (up to 6 hours) postdose
Reported as:
Geometric mean · nM*h
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
nM*hAlisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21D
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 2114846 ± 69.716528 ± 35.6
PrimaryTerminal Half-Life (t1/2) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame:
Cycle 1 Day 21 predose and at multiple time points (up to 6 hours) postdose
Reported as:
Mean · h
Terminal Half-Life (t1/2) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
hAlisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21D
Terminal Half-Life (t1/2) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 2120.5 ± 7.319.5 ± 6.0
PrimaryAccumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame:
Cycle 1 Day 21 predose and at multiple time points (up to 6 hours) postdose
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
ratioAlisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21D
Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 211.9 ± 1.11.5 ± 0.5
PrimaryPeak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame:
Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose
Reported as:
Mean · ratio
Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
ratioAlisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21D
Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 216.0 ± 4.44.3 ± 1.5
PrimaryCLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame:
Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose
Reported as:
Geometric mean · L/h
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
L/hAlisertib 25mg PIC QD 21DAlisertib 35 mg PIC QD 21D
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 213.2 ± 1134.1 ± 45
PrimaryCmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1
nMAlisertib 35 mg PIC QD 14DAlisertib 45 mg PIC QD 14DAlisertib 65 mg PIC QD 14DAlisertib 90 mg PIC QD 14D
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1726.5 ± 34.81637.0 ± 58.01773.4 ± 44.32497.4 ± 24.3
PrimaryCmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
nMAlisertib 35 mg PIC QD 14DAlisertib 45 mg PIC QD 14DAlisertib 65 mg PIC QD 14D
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 142193.5 ± NA1634.4 ± 52.52300.2 ± 40.3
PrimaryTmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1
hAlisertib 35 mg PIC QD 14DAlisertib 45 mg PIC QD 14DAlisertib 65 mg PIC QD 14DAlisertib 90 mg PIC QD 14D
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 12.0 ± 34.83.0 ± 58.02.0 ± 44.32.9 ± 24.3
PrimaryTmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
hAlisertib 35 mg PIC QD 14DAlisertib 45 mg PIC QD 14DAlisertib 65 mg PIC QD 14D
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 143.4 ± NA2.0 ± 52.52.0 ± 40.3
PrimaryAUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Geometric mean · nM*h
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
nM*hAlisertib 35 mg PIC QD 14DAlisertib 45 mg PIC QD 14DAlisertib 65 mg PIC QD 14D
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1423444 ± NA19671 ± 64.828864 ± 39.9
PrimaryAccumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
ratioAlisertib 35 mg PIC QD 14DAlisertib 45 mg PIC QD 14DAlisertib 65 mg PIC QD 14D
Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 142.4 ± 0.001.5 ± 0.51.9 ± 1.6
PrimaryPeak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Mean · ratio
Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
ratioAlisertib 35 mg PIC QD 14DAlisertib 45 mg PIC QD 14DAlisertib 65 mg PIC QD 14D
Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 144.1 ± NA5.4 ± 1.94.4 ± 0.8
PrimaryCLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Geometric mean · L/h
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
L/hAlisertib 35 mg PIC QD 14DAlisertib 45 mg PIC QD 14DAlisertib 65 mg PIC QD 14D
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 142.9 ± NA4.3 ± 444.3 ± 53
PrimaryCmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1
nMAlisertib 40 mg ECT QD 14D
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 11227 ± 41.3
PrimaryCmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
nMAlisertib 40 mg ECT QD 14D
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 141608 ± NA
PrimaryTmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1
hAlisertib 40 mg ECT QD 14D
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 13.9 ± NA
PrimaryTmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
hAlisertib 40 mg ECT QD 14D
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 145.0 ± NA
PrimaryAUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Geometric mean · nM*h
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
nM*hAlisertib 40 mg ECT QD 14D
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1414306 ± 20.3
PrimaryTerminal Half Life for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Mean · h
Terminal Half Life for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
hAlisertib 40 mg ECT QD 14D
Terminal Half Life for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1411.7 ± NA
PrimaryPeak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Mean · ratio
Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
ratioAlisertib 40 mg ECT QD 14D
Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 142.1 ± NA
PrimaryCLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame:
Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Reported as:
Mean · L/h
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
L/hAlisertib 40 mg ECT QD 14D
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 142.5 ± NA
PrimaryCmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1
nMAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1886 ± 39.71114 ± 37.11531 ± 58.4
PrimaryCmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame:
Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
nMAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 72025 ± 29.62586 ± 35.72058 ± 44.6
PrimaryTmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1
hAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 12.0 ± 39.72.2 ± 37.12.0 ± 58.4
PrimaryTmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame:
Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
hAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 72.0 ± 39.72.2 ± 37.12.0 ± 58.4
PrimaryAUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1
Time frame:
Cycle 1 Days 1 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Geometric mean · nM*hr
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1
nM*hrAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 15518 ± 18.37095 ± 42.59732 ± 48.5
PrimaryAUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame:
Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Geometric mean · nM*hr
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
nM*hrAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 716024 ± 20.318624 ± 27.317914 ± 48.6
PrimaryTerminal Half-Life (t1/2) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame:
Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Mean · h
Terminal Half-Life (t1/2) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
hAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
Terminal Half-Life (t1/2) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 713.3 ± NA19.9 ± 10.718.4 ± 13.9
PrimaryAccumulation Ratio (Rac) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame:
Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
ratioAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
Accumulation Ratio (Rac) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 72.9 ± 0.52.8 ± 1.02.3 ± 0.9
PrimaryPeak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame:
Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Mean · ratio
Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
ratioAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 72.5 ± 0.62.4 ± 0.52.5 ± 2.2
PrimaryCLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame:
Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Reported as:
Geometric mean · L/h
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
L/hAlisertib 30 mg ECT BID 7DAlisertib 40 mg ECT BID 7DAlisertib 50 mg ECT BID 7D
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 73.7 ± 0.74.4 ± 1.96.7 ± 5.6
SecondaryBest Overall Response Rate Based on Investigator's Assessment

Best overall response rate is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the Investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and the definition for PR includes at least a 50% decrease in sum of the product of the diameters and no new lesions.

Time frame:
Baseline and every 2 cycles up to Month 12 until disease progression, 30 days after end of treatment (up to 422 days)
Reported as:
Number · percentage of participants
Best Overall Response Rate Based on Investigator's Assessment
percentage of participantsPart 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCL
Best Overall Response Rate Based on Investigator's Assessment139100
SecondaryDuration of Response (DOR)

DOR is defined as the time from the date of first documentation of a response (either CR or PR) to the date of first documentation of progressive disease (PD) according to International Working Group (IWG) criteria. CR is defined as the disappearance of all evidence of disease and the definition for PR includes at least a 50% decrease in sum of the product of the diameters and no new lesions. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.

Time frame:
Baseline and every 2 cycles up to Month 12 until disease progression, 30 days after end of treatment (up to 422 days)
Reported as:
Median · months
Duration of Response (DOR)
monthsPart 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCL
Duration of Response (DOR)0.03 (0.03 to 3.65)2.07 (0.03 to 4.18)0.03 (0.03 to 0.03)
SecondaryNumber of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1

One peripheral blood sample (approximately 4 mL) was to be obtained on Day 1 of Cycle 1 prior to the first dose of alisertib to genotype participants for polymorphisms in UGT1A1 because UGT1A1 is one of the enzymes responsible for glucuronidation of alisertib, which is expected to contribute to the clearance of alisertib. wt=wild type. \*28=polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression. Not determined = blood sample was not evaluable.

Time frame:
Cycle 1 Day 1 predose
Reported as:
Number · participants
Number of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1
participantsAlisertib
wt/wt23
wt/*2823
*28/*288
other/other1
Not Determined2
Missing1
SecondaryNumber of Participants With Polymorphisms in Aurora A Kinase
Time frame:
Cycle 1 Day 1 predose

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study drug to 30 days after the last dose (up to 422 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 PIC Dose Escalation—12/28 (42.9%)28/28 (100%)
Part 1 ECT Dose Escalation—15/28 (53.6%)28/28 (100%)
Part 2 PTCL—2/2 (100%)2/2 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventPart 1 PIC Dose EscalationPart 1 ECT Dose EscalationPart 2 PTCL
Staphylococcal bacteraemiaInfections and infestations0/280/281/2
Herpes zosterInfections and infestations0/280/281/2
DeliriumPsychiatric disorders0/280/281/2
Lung infectionInfections and infestations0/280/281/2
Abdominal painGastrointestinal disorders0/280/281/2
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/280/281/2
Respiratory failureRespiratory, thoracic and mediastinal disorders0/280/281/2
Febrile neutropeniaBlood and lymphatic system disorders1/284/280/2
Musculoskeletal painMusculoskeletal and connective tissue disorders2/280/280/2
Small intestinal obstructionGastrointestinal disorders0/282/280/2
Most frequent other events
Showing 10 of 78
Most frequent other events
EventPart 1 PIC Dose EscalationPart 1 ECT Dose EscalationPart 2 PTCL
NeutropeniaBlood and lymphatic system disorders13/2818/282/2
ThrombocytopeniaBlood and lymphatic system disorders11/2813/282/2
AnaemiaBlood and lymphatic system disorders11/2812/282/2
ConstipationGastrointestinal disorders2/285/282/2
StomatitisGastrointestinal disorders3/282/282/2
HypokalaemiaMetabolism and nutrition disorders3/287/282/2
LeukocytosisBlood and lymphatic system disorders0/280/281/2
SplenomegalyBlood and lymphatic system disorders0/280/281/2
DiarrhoeaGastrointestinal disorders9/2814/281/2
Dry mouthGastrointestinal disorders4/281/281/2

Baseline characteristics

Safety population is defined as all participants who received any amount of alisertib.

Age, Continuous
Age, Continuous(years)Part 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCLTotal
Mean61.4 ± 8.9159.5 ± 14.2263.0 ± 24.0460.5 ± 12.03
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCLTotal
Female1415231
Male1413027
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCLTotal
Hispanic or Latino97016
Not Hispanic or Latino1920241
Unknown or Not Reported0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Part 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCLTotal
White2426252
Black or African American3104
Asian0101
Not Reported1001
Region of Enrollment
Region of Enrollment(participants)Part 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCLTotal
United States2828258
Height
Height(cm)Part 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCLTotal
Mean165.9 ± 11.25164.6 ± 10.95160.6 ± 6.43165.1 ± 10.89
Weight
Weight(kg)Part 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCLTotal
Mean81.40 ± 20.03177.62 ± 19.74797.65 ± 43.91180.13 ± 20.573
Body Surface Area
Body Surface Area(m^2)Part 1: PIC Dose EscalationPart 1: ECT Dose EscalationPart 2: PTCLTotal
Mean1.93 ± 0.2821.88 ± 0.2892.05 ± 0.4341.91 ± 0.286
08

Study locations

10 sites
  • Scottsdale, Arizona, United States
  • Lexington, Kentucky, United States
  • Baltimore, Maryland, United States
  • Omaha, Nebraska, United States
  • Hackensack, New Jersey, United States
  • Buffalo, New York, United States
  • Chapel Hill, North Carolina, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
09

References and documents

Publications

  • Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Iyer SP. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2014 Jun;32(3):489-99. doi: 10.1007/s10637-013-0050-9. Epub 2013 Dec 20. PubMed 24352795 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2008 to primary completion in Oct 2016, 98 months.

Results were first posted in May 2019, 2 years 7 months after primary completion.

Of 81 phase 1 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 102. This study's 98 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2008
First posted
Jun 13, 2008
StartActual
Jul 11, 2008
Primary completionActual
Oct 1, 2016
CompletionActual
Oct 19, 2016
Results first posted
May 31, 2019
Last update
May 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00697346
Responsible party
Sponsor
First posted
Jun 13, 2008
Start date
Jul 11, 2008
Primary completion
Oct 1, 2016
Completion
Oct 19, 2016
Results posted
May 31, 2019
Last update
May 31, 2019

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion